SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

F1ash, your quote referencing their poster describes Part

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (4) | Next 10 | Previous | Next
seventhwave Member Profile
 
Followed By 6
Posts 255
Boards Moderated 0
Alias Born 01/07/10
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 12/15/2017 4:13:15 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 12/15/2017 4:11:28 PM
Annual Report (10-k) "Edgar (US Regulatory)" - 12/11/2017 5:17:35 PM
Anavex Life Sciences Reports Fiscal 2017 Financial Results And Provides Update On Therapeutic Programs "GlobeNewswire Inc." - 12/11/2017 7:00:00 AM
Anavex Life Sciences Reports Newly Published Data on Alzheimer's Disease Research Demonstrate the Neuroprotective Features of... "GlobeNewswire Inc." - 11/21/2017 7:00:00 AM
Anavex Life Sciences to Present at the 5th Annual Mental Health Parity Addiction Equity Act Business Roundtable in Washington... "GlobeNewswire Inc." - 11/8/2017 7:00:00 AM
Anavex Life Sciences Presents New Clinical Data of Investigational Alzheimer’s Disease Treatment ANAVEX®2-73 at 2017 Clini... "GlobeNewswire Inc." - 11/4/2017 3:30:00 PM
Greenbank Cap, Inc. (OTC Pink: GRNBF) Closes Private Placement as Shares Climb "InvestorsHub NewsWire" - 10/30/2017 7:00:00 AM
Anavex Life Sciences Announces Additional Data at The Michael J. Fox Foundation’s Parkinson's Disease Therapeutics Conferen... "GlobeNewswire Inc." - 10/30/2017 7:00:00 AM
Anavex Life Sciences Announces New Data Related to Multiple Sclerosis Presented at 7th ECTRIMS-ACTRIMS Meeting MSPARIS2017 "GlobeNewswire Inc." - 10/27/2017 8:52:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/26/2017 2:50:54 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/24/2017 12:06:59 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/19/2017 6:47:52 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/18/2017 9:47:41 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/16/2017 11:07:52 AM
Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX®2-73 in Mild-to-Moderate Alzheimer’s Disease Pat... "GlobeNewswire Inc." - 10/12/2017 7:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/6/2017 5:18:01 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/5/2017 5:57:37 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/2/2017 7:53:34 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/29/2017 2:33:03 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/26/2017 3:10:51 PM
Anavex Life Sciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference "GlobeNewswire Inc." - 9/21/2017 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/20/2017 4:51:51 PM
Biotech's Recently Under the Microscope, Analyst Coverage "InvestorsHub NewsWire" - 9/20/2017 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/19/2017 1:59:44 PM
seventhwave   Thursday, 10/12/17 10:57:54 PM
Re: F1ash post# 124384
Post # of 134637 
F1ash, your quote referencing their poster describes Part B while I was alluding to Part C. I was using your clarification there, that Part C is really a completely new trial to speculate that it would give them the freedom to adjust the lower doses. I assumed that they were constrained from doing so by Part A + Part B protocol and not patient tolerability. If they attempted to titrate up and reached the tolerability bounds earlier then my guess of their flexibility to do so in Part C is redundant.

Separately, I'm not sure why Dr. Perry said that the case of a drug improving or benefiting patients through a long period has never been witnessed before when you have shown results from the Flurizipan study in detailed charts, clearly showing about a good 18% showing retained improvement at the 12 month interval.

I'm not sure why Dr. Perry was on the call (as 3rd party) in the first place. It's as if Missling were implying "if you don't believe in the data or what Anavex is saying then listen to this editor of the Journal of AD". Esp. when he has a galaxy of stars in the Anavex SAB. Beats me.


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (4) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist